COVID-19: Immunology, Immunopathogenesis and Potential Therapies

References

• Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220. doi:.
   PubMed Web of Science ®Google Scholar
• Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506–510. doi:.
   PubMed Web of Science ®Google Scholar
• Hassan SA, Sheikh FN, Jamal S, et al. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. doi:.
   PubMed Web of Science ®Google Scholar
• Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432. doi:.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi:.
   PubMed Web of Science ®Google Scholar
• Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452. doi:.
   PubMed Web of Science ®Google Scholar
• Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976. doi:.
   PubMed Web of Science ®Google Scholar
• Cheng VC, Lau SK, Woo PC, et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):660–694. doi:.
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–1966. doi:.
   PubMed Web of Science ®Google Scholar
• Ramadan N, Shaib H. Middle East respiratory syndrome coronavirus (MERS-CoV): a review. Germs. 2019;9(1):35–42. doi:.
   PubMedGoogle Scholar
• de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790–7792. doi:.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224. doi:.
   PubMed Web of Science ®Google Scholar
• Lei C, Qian K, Li T, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11(1):2070. doi:.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:.
   PubMed Web of Science ®Google Scholar
• Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325–328. doi:.
   PubMed Web of Science ®Google Scholar
• Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237–261. doi:.
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23. doi:.
   PubMedGoogle Scholar
• Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2020;38:1–10.
   PubMed Web of Science ®Google Scholar
• Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of Coronavirus Disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi:.
   PubMed Web of Science ®Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of Coronavirus Disease 2019 (COVID-19) From publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582. doi:.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:.
   PubMed Web of Science ®Google Scholar
• Vaira LA, Salzano G, Deiana G, et al. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. 2020;130(7):1787. doi:.
   PubMed Web of Science ®Google Scholar
• Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. doi:.
   PubMed Web of Science ®Google Scholar
• de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Brazilian diabetes society study G. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020;12(1):75. doi:.
   PubMed Web of Science ®Google Scholar
• Poletti P, Tirani M, Cereda D, et al. Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020. Eurosurveillance. 2020;25(31):2001383. doi:.
   Google Scholar
• Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. doi:.
   PubMed Web of Science ®Google Scholar
• Huang J, Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol. 2020;92(10):2152–2158. doi:.
   PubMed Web of Science ®Google Scholar
• Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2?Am J Physiol Renal Physiol. 2020;318(6):F1454–F1462. doi:.
   PubMed Web of Science ®Google Scholar
• Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–430. doi:.
   PubMed Web of Science ®Google Scholar
• Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247–250. doi:.
   PubMed Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi:.
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi:.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi:.
   PubMed Web of Science ®Google Scholar
• Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618. doi:.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006;6(3):271–276. doi:.
   PubMed Web of Science ®Google Scholar
• Sims AC, Baric RS, Yount B, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79(24):15511. doi:-1515524.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. doi:.
   PubMed Web of Science ®Google Scholar
• Babcock GJ, Esshaki DJ, Thomas WD, Jr., et al. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol. 2004;78(9):4552–4560. doi:.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525(1):135–140. 2020. doi:.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi:.
   PubMed Web of Science ®Google Scholar
• Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. doi:.
   PubMed Web of Science ®Google Scholar
• Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927. doi:.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:.
   PubMed Web of Science ®Google Scholar
• Zhao J, Van Rooijen N, et al. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog 2009;5(10):e1000636. doi:
   Google Scholar
• Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407–1409. doi:.
   PubMed Web of Science ®Google Scholar
• Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol 2015;67(11):3037–3046. doi:
   Google Scholar
• Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi:.
   PubMed Web of Science ®Google Scholar
• Weber AG, Chau AS, Egeblad M, et al. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series. medRxiv. 2020.
   Google Scholar
• Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020;95:183–191. doi:.
   PubMed Web of Science ®Google Scholar
• Kritas SK, Ronconi G, Caraffa A, et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents 2020;34(1):9–14. doi:
   Google Scholar
• Ronconi G, Teté G, Kritas SK, et al. SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. J Biol Regul Homeost Agents 2020;34(3):767–773. doi:
   Google Scholar
• Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Research Square. 2020:rs.3.rs-30934. doi:
   Google Scholar
• Gigante A, Aquili A, Farinelli L, et al. Sodium chromo-glycate and palmitoylethanolamide: a possible strategy to treat mast cell-induced lung inflammation in COVID-19. Med Hypotheses. 2020;143:109856. doi:.
   PubMed Web of Science ®Google Scholar
• Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors. 2020;46(3):306–308. doi:.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496. doi:.
   PubMed Web of Science ®Google Scholar
• Felsenstein S, Herbert JA, McNamara PS, et al. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448. doi:.
   PubMed Web of Science ®Google Scholar
• Versteeg GA, Bredenbeek PJ, van den Worm SHE, et al. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology. 2007;361(1):18–26. doi:.
   PubMed Web of Science ®Google Scholar
• Narayanan K, Huang C, Lokugamage K, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471–4479. doi:.
   PubMed Web of Science ®Google Scholar
• Kindler E, Thiel V, Weber F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv Virus Res. 2016;96:219–243. doi:.
   PubMed Web of Science ®Google Scholar
• Sun L, Xing Y, Chen X, et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One. 2012;7(2):e30802. doi:.
   PubMed Web of Science ®Google Scholar
• Siu KL, Chan CP, Kok KH, et al. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol. 2014;11(2):141–149. doi:.
   PubMed Web of Science ®Google Scholar
• Cheung CY, Poon LL, Ng IH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819–7826. doi:.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. doi:.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9. doi:.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients. Science 2020;369(6504):718–724. doi:
   Google Scholar
• Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–469. doi:.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:.
   PubMed Web of Science ®Google Scholar
• Rayamajhi M, Zhang Y, Miao EA. Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods Mol Biol. 2013;1040:85–90. doi:.
   PubMedGoogle Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:.
   PubMed Web of Science ®Google Scholar
• Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15(5):700–704. doi:.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19?Nat Rev Immunol. 2020;20(6):343–344. doi:.
   PubMed Web of Science ®Google Scholar
• Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146(1):215–217.
   PubMed Web of Science ®Google Scholar
• Guo C, Li B, Ma H, et al. Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis. bioRxiv. 2020. doi:
   Google Scholar
• Llitjos J-F, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743–1746. doi:.
   PubMed Web of Science ®Google Scholar
• Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268–2270. doi:.
   PubMed Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13. doi:.
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. 2020.
   Google Scholar
• de Marcken M, Dhaliwal K, Danielsen AC, et al. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci Signal. 2019;12(605):eaaw1347. doi:.
   PubMedGoogle Scholar
• Liao M, Liu Y, Yuan J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. Nature Medicine 2020;26:842–844.
   Google Scholar
• Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stageby single-cell sequencing. Cell Discov. 2020;6(1):31. doi:.
   PubMed Web of Science ®Google Scholar
• Ong EZ, Chan YFZ, Leong WY, et al. A dynamic immune response shapes COVID-19 progression. Cell Host Microbe. 2020;27(6):879–882.e2. doi:.
   PubMedGoogle Scholar
• Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970–979. doi:.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992–1000.e3. doi:.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016;8(8):959–970. doi:
   Google Scholar
• Chen IY, Moriyama M, Chang MF, et al. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 2019;10:50 doi:
   Google Scholar
• Huang L, Shi Y, Gong B, et al. Blood single cell immune profiling reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19. medRxiv. 2020. doi:.
   Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020;383(24):2333–2344. doi:.
   PubMed Web of Science ®Google Scholar
• Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. 2020;5(49):eabd1554. doi:.
   PubMedGoogle Scholar
• Bao L, Deng W, Gao H, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 2020. doi:.
   Google Scholar
• Chen y, Feng Z, Diao B, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv 2020. ­doi:.
   Google Scholar
• Peebles RS, Jr., Graham BS. Viruses, dendritic cells and the lung. Respir Res. 2001;2(4):245–249. doi:.
   PubMed Web of Science ®Google Scholar
• Spiegel M, Schneider K, Weber F, et al. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J Gen Virol 2006;87(Pt 7):1953–1960. doi:.
   Google Scholar
• Taghizadeh-Hesary F, Akbari H. The powerful immune system against powerful COVID-19: a hypothesis. Med Hypotheses. 2020;140:109762. doi:.
   PubMed Web of Science ®Google Scholar
• Law HKW, Cheung CY, Sia SF, et al. Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells. BMC Immunol. 2009;10:35. doi:.
   PubMedGoogle Scholar
• Lau YL, Peiris J, Law HKW, et al. Role of dendritic cells in SARS coronavirus infection. Hong Kong Med J 2012;18(Suppl 3):28–30.
   Google Scholar
• Tseng CT, Perrone LF-ZH, Zhu H, et al. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol 2005;174(12):7977–7985. doi:.
   Google Scholar
• Chu H, Zhou J, Wong BH, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 2014;454-455:197–205. doi:.
   Google Scholar
• Wilk A, Rustagi A, Zhao N, et al. A single-cell atlas of the peripheral immune response to severe COVID-19. Nature Medicine 2020;26(7):1070–1076.
   Google Scholar
• Arunachalam PS, Wimmers F, Mok CKP, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369(6508):1210–1220. doi:.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Marti JLG, Nasrazadani A, et al. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med. 2020;18(1):261. doi:.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ren L, Zhang L, et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe. 2020;27(6):883–890e2. doi:.
   Google Scholar
• Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–1301. doi:.
   PubMed Web of Science ®Google Scholar
• Turner BC, Hemmila E, Beauchemin N, et al. Receptor-dependent coronavirus infection of dendritic cells. J Virol. 2004;78(10):5486–5490. doi:.
   Google Scholar
• Jeffers SA, Tusell SF-G-RL, Gillim-Ross L F-HE, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 2004;101(44):15748–15753. doi:.
   Google Scholar
• Duev-Cohen A, Bar-On Y, Glasner A, et al. The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity. Oncotarget. 2016;7(11):13093–13105. doi:.
   PubMedGoogle Scholar
• Glasner A, Zurunic A, Meningher T, et al. Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS One. 2012;7(5):e36837. doi:.
   PubMed Web of Science ®Google Scholar
• Draghi M, Pashine A, Sanjanwala B, et al. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol. 2007;178(5):2688–2698. doi:.
   PubMed Web of Science ®Google Scholar
• van Erp EA, van Kampen MR, van Kasteren PB, et al. Viral infection of human natural killer cells. Viruses. 2019;11(3):243. doi:.
   Google Scholar
• Yu L, Tong Y, Shen G, et al. Immunodepletion with hypoxemia: a potential high risk subtype of Coronavirus Disease 2019. medRxiv, 2020. doi:.
   Google Scholar
• Maucourant C, Filipovic I, Ponzetta A, et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020;5(50):eabd6832. doi:.
   PubMed Web of Science ®Google Scholar
• Mao H, Tu W, Gin Q, et al. Influenza virus directly infects human natural killer cells and induces cell apoptosis. J Virol. 2009;83(18):9215–9222. doi:.
   Google Scholar
• Travaglini KJ, Nabhan AN, Penland L, et al. A molecular cell atlas of the human lung from single cell RNA sequencing. Nature. 2020;587:619–625.
   Web of Science ®Google Scholar
• Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types?Front Physiol. 2018;9:113. doi:.
   PubMed Web of Science ®Google Scholar
• Galani IE, Andreakos E. Neutrophils in Viral Infections: Current Concepts and Caveats. J Leukoc Biol. 2015;98(4):557–564. doi:.
   Google Scholar
• Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134–147. doi:.
   PubMed Web of Science ®Google Scholar
• Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost. 2019;45(1):86–93. doi:.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Zuo M, Yalavarthi S, et al. Neutrophil Extracellular Traps and Thrombosis in COVID-19. medRxiv. 2020. doi:.
   Google Scholar
• Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020;15(7):e0235458. doi:.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Z, Xiong G. Clinical characteristics and laboratory results of pregnant women with COVID-19 in Wuhan. Int J Gynecol Obstet. 2020;150(3):312–317. doi:.
   PubMedGoogle Scholar
• Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511. doi:.
   PubMed Web of Science ®Google Scholar
• Tomar B, Anders H-J, Desai J, et al. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. Cells. 2020;9(6):1383. doi:.
   PubMed Web of Science ®Google Scholar
• Mahallawi WH, Khabour OF, Zhang Q, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13. doi:.
   PubMed Web of Science ®Google Scholar
• Shi H, Zuo Y, Yalavarthi S, et al. Neutrophil Calprotectin Identifies Severe Pulmonary Disease in COVID-19. medRxiv. 2020. doi:.
   Google Scholar
• Yaqinuddin A, Kashir J. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: targeting a potential IL-1н╡/neutrophil extracellular traps feedback loop. Med Hypotheses 2020;143:109906. doi:.
   Google Scholar
• Veras FP, Pontelli MC, Silva CM, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med. 2020;217(12). doi:.
   Web of Science ®Google Scholar
• Thierry AR. Does the newly observed inflammatory syndrome in children demonstrate a link between uncontrolled neutrophil extracellular traps formation and COVID-19? Pediatr Res. 2020. doi:.
   Google Scholar
• Siracusa MC, Kim BS, Spergel JM, et al. Basophils and allergic inflammation. J Allergy Clin Immunol. 2013;132(4):789–788. doi:.
   PubMed Web of Science ®Google Scholar
• Chirumbolo S. State-of-the-art review about basophil research in immunology and allergy: is the time right to treat these cells with the respect they deserve?Blood Transfus. 2012;10(2):148–164. doi:.
   PubMed Web of Science ®Google Scholar
• Clementsen P, Jensen CB ,Jarløv , JO, et al. Virus enhances histamine release from human basophils. Agents Actions 1988;23(3–4):165–167. doi:.
   Google Scholar
• Jiang A-P, Jiang J-F, Guo M-G, et al. Human blood-circulating basophils capture HIV-1 and Mediate Viral trans-infection of CD4+ T cells. J Virol. 2015;89(15):8050–8062.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi:.
   PubMed Web of Science ®Google Scholar
• Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020;146(1):1–7. doi:.
   PubMed Web of Science ®Google Scholar
• Bao J, Li C, Zhang K, et al. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta. 2020;509:180–194. doi:.
   PubMedGoogle Scholar
• Lu G, Wang J. Dynamic changes in routine blood parameters of a severe COVID-19 case. Clinica Chimica Acta 2020;508. doi:.
   Google Scholar
• Chen R, Sang L, Jiang M, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020;146(1):89–100. doi:.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhi YA-O, Ying S. COVID-19 and asthma: reflection during the pandemic. Clinical Reviews in Allergy & Immunology 2020;59(1):78–88.
   Google Scholar
• Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Frontiers in immunology 2016;6(620).
   Google Scholar
• Hu Y, Jin Y, Han D, et al. Mast cell-induced lung injury in mice infected with H5N1 influenza virus. J Virol. 2012;86:3347–3356.
   Google Scholar
• Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. IJMS. 2019;20(17):4241. doi:.
   Google Scholar
• Ramos L, Peña G, Cai B, et al. Mast cell stabilization improves survival by preventing apoptosis in sepsis. J Immunol. 2010;185(1):709–716. doi:.
   PubMedGoogle Scholar
• Sestili P, Stocchi V. Repositioning chromones for early anti-inflammatory treatment of COVID-19. Front Pharmacol. 2020;11:854. doi:.
   PubMedGoogle Scholar
• Veerappan A, Reid AC, Estephan R, et al. Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction. Proceedings of the National Academy of Sciences 2008;105(4):1315–1320.
   Google Scholar
• Caughey GH, Raymond W, Wolters PJ, et al. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta 2000;1480(1–2):245–257. doi:.
   Google Scholar
• Miller HR, Pemberton AD. Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut. Immunology 2002;105(4):375–390. doi:.
   Google Scholar
• Cui W, Fan Y, Wu W, et al. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003;37(6):857–859. doi:.
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11(827). doi:.
   Google Scholar
• Satija N, Lal SK. The molecular biology of SARS coronavirus. Ann N Y Acad Sci. 2007;1102:26–38. doi:.
   PubMed Web of Science ®Google Scholar
• Shiow LR, Rosen DB, Brdickova N, et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 2006;440(7083):540–544. doi:.
   PubMed Web of Science ®Google Scholar
• Campbell KM, Steiner G, Wells DK, et al. Prediction of SARS-CoV-2 Epitopes across 9360 HLA Class I Alleles. bioRxiv. 2020. doi:.
   Google Scholar
• Li CK-f, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490–5500. doi:.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48):eabd2071. doi:.
   Google Scholar
• Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89–94. doi:.
   PubMed Web of Science ®Google Scholar
• Poston D, Weisblum Y, Wise H, et al. Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection. medRxiv. 2020. doi:.
   Google Scholar
• Anderson EM, Goodwin EC, Verma A, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection: medRxiv. 2020. doi:.
   Google Scholar
• Edridge AWD, Kaczorowska JM, Hoste ACR, et al Coronavirus protective immunity is short-lasting Nature Medicine 2020;26(11):1691–1693.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998–1002.
   PubMed Web of Science ®Google Scholar
• Huang H, Wang S, Jiang T, et al. High levels of circulating GM-CSF + CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study. Cell Mol Immunol. 2019;16(6):602–610. doi:.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:.
   PubMed Web of Science ®Google Scholar
• Zheng J, Liu Y, Lau Y-L, et al . нЁн╢-T cells: an Unpolished sword in human anti-infection immunity. Cell Mol Immunol 2013;10(1):50–57. doi:.
   Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF + T cells and inflammatory CD14 + CD16+. Monocytes in severe pulmonary syndrome patients of a new coronavirus. National Science Review 2020. doi:.
   Google Scholar
• Walter JM, Helmin KA, Abdala-Valencia H, et al. Multidimensional assessment of alveolar T cells in critically ill patients. JCI Insight 2018;3(17):e123287. doi:.
   Google Scholar
• Dong C, Ni L, Ye F, et al. Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2. medRxiv. 2020. doi:.
   Google Scholar
• Lei L, Qian H, Yang X.et al. The phenotypic changes of γδ T cells in COVID-19 patients. J Cel Mol Med. 2020;24(19):11603–11606.
   Google Scholar
• Kaneko N, Kuo HH, Boucau J, et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. 2020;183(1):143–157. doi:.
   PubMed Web of Science ®Google Scholar
• Jouan Y, Guillon A, Gonzalez L, et al. Functional alteration of innate T cells in critically ill COVID-19 patients. medRxiv. 2020. doi:.
   Google Scholar
• Libraty DH, O’Neil KM, Baker LM, et al. Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection. Virol. 2007;368(2):317–321. doi:.
   Google Scholar
• Fan Y-Y, Huang Z-T, Li L, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol. 2009;154(7):1093–1099. doi:.
   PubMed Web of Science ®Google Scholar
• Tang F, Quan Y, Xin Z-T, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186(12):7264–7268. doi:.
   PubMed Web of Science ®Google Scholar
• Ng OW, Chia A, Tan AT, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.Vaccine 2016;34(17):2008–2014. doi:.
   Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. Science 2020;371(6529):eabf4063.
   Google Scholar
• Hsueh PR, Huang L, Chen PJ, et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062–1066. doi:.
   Google Scholar
• Haveri A, Smura T, Kuivanen S, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveillance 2020;25(11):2000266.
   Google Scholar
• To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574. doi:.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge X, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. Nat. 2020;584(7819):115–119.
   Google Scholar
• Zhang L, Zhang F, Yu W, et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol. 2006;78(1):1–8. doi:.
   Google Scholar
• Cao W, Liu W, Zhang P-H, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–1163. doi:.
   Google Scholar
• Liu W, Fontanet A, Zhang P-H, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792–795. doi:.
   Google Scholar
• Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Medicine 2004;10(8):871–875.
   Google Scholar
• Payne DC, Iblan I, Rha B, et al. Persistence of antibodies against middle east respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824–1826. doi:.
   PubMed Web of Science ®Google Scholar
• Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–455.
   Google Scholar
• Addetia A, Crawford KH, Dingens A, et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with High Attack Rate. Virol. 2020. doi:.
   Google Scholar
• Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–1734. doi:.
   Google Scholar
• Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Nat Microbiol. 2020. doi:.
   Google Scholar
• To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020:ciaa1275. doi:.
   Google Scholar
• Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–1230. doi:.
   PubMed Web of Science ®Google Scholar
• Taylor A, Foo S-S, Bruzzone R, et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev. 2015;268(1):340–364. doi:.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. Virol. 2020;94(5):e02015–19.
   Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158. doi:.
   Google Scholar
• Yip M, Leung NHL, Leung N, et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. 2014.
   Google Scholar
• Quinlan BD, Mou H, Zhang L, et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. bioRxiv. 2020. doi:.
   Google Scholar
• Chen J, Kelley WJ, Goldstein DR. Role of aging and the immune response to respiratory viral infections: potential implications for COVID-19. JI. 2020;205(2):313–320. doi:.
   Google Scholar
• Zhao J, Zhao J, Legge K, et al. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011;121(12):4921–4930. doi:.
   PubMed Web of Science ®Google Scholar
• Nikolich-Zugich J, Knox KS, Rios CT, et al. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020;42(2):505–514. doi:.
   PubMed Web of Science ®Google Scholar
• Lingappan K, Karmouty-Quintana H, Davies J, et al. Understanding the age divide in COVID-19: why are children overwhelmingly spared? Am J Physiol Lung Cell Mol Physiol. 2020;319(1):L39–L44. doi:.
   PubMedGoogle Scholar
• Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 Coronavirus Disease in China. Pediatrics. 2020;145(6):e20200702. doi:.
   PubMed Web of Science ®Google Scholar
• Jing Q-L, Liu M-J, Yuan J, et al. Household secondary attack rate of COVID-19 and associated determinants. medRxiv. 2020. doi:.
   Google Scholar
• Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric SARS-CoV-2: clinical presentation, infectivity, and immune responses. J Pediatr. 2020;227:45–52.e5. doi:.
   PubMed Web of Science ®Google Scholar
• Chen C, Qi F, Shi K, et al. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019. Clin Transl Med. 2020;10(2):e35. doi:.
   PubMedGoogle Scholar
• Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761. doi:.
   PubMed Web of Science ®Google Scholar
• Humanigen. Humanigen Partners with CTI, a Leading Contract Research Organization, for Planned Phase III Study for Lenzilumab for Coronavirus Treatment. Burlingame, CA and Covington, KY: Humanigen; 2020.
   Google Scholar
• Sciences R. Roivant announces development of anti-GM- CSF monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19. Roivant Sciences 2020.
   Google Scholar
• Bioscience I. Initiation of two- centre compassionate use study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy. Izana Bioscience 2020.
   Google Scholar
• Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–283. doi:.
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42(2):145–153. doi:.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739. doi:.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. doi:.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines. J Med Virol. 2020;92(9):1495–1500. doi:.2020.
   Google Scholar
• Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548. doi:.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. 2005. doi:.
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–456. doi:.
   PubMed Web of Science ®Google Scholar
• Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617–622. doi:.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158(1):e9–e13. doi:.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. 2020. doi:.
   PubMed Web of Science ®Google Scholar
• Tanne JH. COVID-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi:.
   Google Scholar
• Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42(1):15–31. doi:.
   PubMed Web of Science ®Google Scholar
• Timmermans S, Souffriau J, Libert C. A general introduction to glucocorticoid biology. Front Immunol. 2019;10:1545. doi:.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767. 2018. doi:.
   PubMed Web of Science ®Google Scholar
• Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):e98–e106. doi:.
   PubMed Web of Science ®Google Scholar
• Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with Coronavirus Disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–420. doi:.
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. doi:.
   PubMed Web of Science ®Google Scholar
• Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020;582(7813):469–469. doi:.
   PubMed Web of Science ®Google Scholar
• Selvaraj J, Sardar H, Vishnupriya V, et al. Molecular docking analysis of amyloid precursor protein with compounds from the Australian cowplant. Bioinformation. 2020;16(7):561–566. doi:.
   PubMedGoogle Scholar
• Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–150. doi:.
   PubMed Web of Science ®Google Scholar
• Manjili RH, Zarei M, Habibi M, et al. COVID-19 as an acute inflammatory disease. J Immunol. 2020;205(1):12–19. doi:.
   PubMed Web of Science ®Google Scholar
• Zheng W, Fan W, Zhang S, et al. Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export. Cell Rep. 2019;27(6):1875–1885. doi:.
   PubMedGoogle Scholar
• Kickbusch I, Leung G. Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406. doi:.
   PubMedGoogle Scholar
• Amici C, Di CA, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11(8):1021–1030.
   PubMed Web of Science ®Google Scholar
• Marinella MA. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. Int J Clin Pract. 2020;74(9):e13535. doi:.
   PubMed Web of Science ®Google Scholar
• Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29(11):491–498. doi:.
   PubMed Web of Science ®Google Scholar
• Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1–11. doi:.
   PubMed Web of Science ®Google Scholar
• Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255 (Suppl 3):3–6. doi:.
   PubMed Web of Science ®Google Scholar
• Mohtadi N, Ghaysouri A, Shirazi S, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. Virology. 2020;548:1–5. doi:.
   PubMed Web of Science ®Google Scholar
• Xie Y, Cao S, Dong H, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81(2):318–356. doi:.
   PubMed Web of Science ®Google Scholar
• Cao W,Liu X,Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum Infectious Dis. 2020;7(3). doi:.
   Google Scholar
• Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11(12):836–848. doi:.
   PubMed Web of Science ®Google Scholar
• de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534. doi:.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. doi:.
   PubMed Web of Science ®Google Scholar
• Pfizer. Pfizer and Biontech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study. 2020.
   Google Scholar
• Hindu T. Coronavirus | Pfizer seeks emergency use authorisation for its COVID-19 vaccine in India. 2020.
   Google Scholar
• Focus R. COVID-19 vaccine tracker. 2020.
   Google Scholar
• Agencies AJAN. Which countries have rolled out COVID vaccine? 2021.
   Google Scholar
• BMJ T. COVID-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ. 2020;371. doi:.
   Google Scholar
• BBC. COVID-19: Oxford University vaccine is highly effective. 2020.
   Google Scholar
• Trials C. Russia’s Sputnik V vaccine shows 92% efficacy in COVID-19 trial. 2020.
   Google Scholar
• Poonawalla A. Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca. BBC News India 2021.
   Google Scholar
• Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–620. doi:.
   PubMed Web of Science ®Google Scholar
• Berry JD, Hay K, Rini JM, et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs. 2010;2(1):53–66. doi:.
   PubMed Web of Science ®Google Scholar
• Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382–385. doi:.
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–655. doi:.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing monoclonal antibodies directed to multiple epitopes on the SARS-CoV-2 spike. Nature. 2020;584:450–456.
   Google Scholar
• Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–588. doi:.
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–1018. doi:.
   PubMed Web of Science ®Google Scholar
• Fan T, Chen Y, Bai Y, et al. Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):260–269. doi:.
   PubMedGoogle Scholar
• Rastogi S, Pandey DN, Singh RH. COVID-19 pandemic: a pragmatic plan for Ayurveda Intervention. J Ayurveda Integr Med. 2020. doi:.
   Web of Science ®Google Scholar
• Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020;16(10):1708–1717. doi:.
   PubMed Web of Science ®Google Scholar
• Chan K, Zhang H, Lin ZX. An overview on adverse drug reactions to traditional Chinese medicines. Br J Clin Pharmacol. 2015;80(4):834–843. doi:.
   PubMedGoogle Scholar
• Khodadadi S. Role of herbal medicine in boosting immune system. Immunopathol Persa. 2015;1(1):e01.
   Web of Science ®Google Scholar
• Singh N, Tma MS. A review on herbal plants as immunomodulators. Int J Pharm Sci Res. 2016;7(9):3602–3610.
   Web of Science ®Google Scholar
• Elsayed Y, Khan NA. Immunity-boosting spices and the novel coronavirus. ACS Chem Neurosci. 2020;11(12):1696–1698. doi:.
   PubMedGoogle Scholar
• Yamamoto M, Matsuyama S, Li X, et al. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60(11):6532–6539. doi:.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 - preliminary report. N Engl J Med. 2020;383(19):1813–1826. doi:.
   PubMed Web of Science ®Google Scholar
• Hunt A. COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19. 2020.
   Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:.
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31. doi:.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293. doi:.
   PubMed Web of Science ®Google Scholar
• Jin Z, Zhao Y, Sun Y, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020;27(6):529–532. doi:.
   PubMed Web of Science ®Google Scholar
• Sommer F, Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227–238. doi:.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. doi:.
   PubMed Web of Science ®Google Scholar
• Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol. 2007;19(2):59–69. doi:.
   PubMedGoogle Scholar
• Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4(6):478–485. doi:.
   PubMed Web of Science ®Google Scholar
• Mazmanian SK, Liu CH, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107–118. doi:.
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638. doi:.
   PubMed Web of Science ®Google Scholar
• Wang B, Yao M, Lv L, et al. The human microbiota in health and disease. Engineering. 2017;3(1):71–82. doi:.
   Web of Science ®Google Scholar
• Williams NT. Probiotics. Am J Health Syst Pharm. 2010;67(6):449–458. doi:.
   PubMed Web of Science ®Google Scholar
• Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183–1196. doi:.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Maiden L, Bjarnason I. Genetic aspects of intestinal permeability in inflammatory bowel disease. Novartis Found Symp. 2004;263:151–158.
   PubMedGoogle Scholar
• Soler AP, Miller RD, Laughlin KV, et al. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis. 1999;20(8):1425–1431. doi:.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2(8413):1171–1174. doi:.
   PubMed Web of Science ®Google Scholar
• Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterol. 2020;159(3):944–955.e8. doi:.
   PubMed Web of Science ®Google Scholar
• Dhar D, Mohanty A. Gut microbiota and COVID-19- possible link and implications. Virus Res. 2020;285:198018. doi:.
   PubMed Web of Science ®Google Scholar
• Yang T, Chakraborty S, Saha P, et al. Gnotobiotic rats reveal that gut microbiota regulates colonic mRNA of Ace2, the receptor for SARS-CoV-2 infectivity. Hypertension. 2020;76(1):e1–e3. doi:.
   PubMedGoogle Scholar
• Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol. 2010;3(5):307–319. doi:.
   PubMedGoogle Scholar
• Diaz de Barboza G, Guizzardi S, Tolosa de Talamoni N. Molecular aspects of intestinal calcium absorption. World J Gastroenterol. 2015;21(23):7142–7154. doi:.
   PubMed Web of Science ®Google Scholar
• Dar HY, Pal S, Shukla P, et al. Bacillus clausii inhibits bone loss by skewing Treg-Th17 cell equilibrium in postmenopausal osteoporotic mice model. Nutrition. 2018;54:118–128. doi:.
   PubMed Web of Science ®Google Scholar
• Dar HY, Shukla P, Mishra PK, et al. Lactobacillus acidophilus inhibits bone loss and increases bone heterogeneity in osteoporotic mice via modulating Treg-Th17 cell balance. Bone Rep. 2018;8:46–56. doi:.
   PubMedGoogle Scholar
• Suez J, Zmora N, Segal E, et al. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–729. doi:.
   PubMed Web of Science ®Google Scholar
• Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644–645. doi:.
   PubMed Web of Science ®Google Scholar
• Sichetti M, De Marco S, Pagiotti R, et al. Anti-inflammatory effect of multistrain probiotic formulation (L. rhamnosus, B. lactis, and B. longum). Nutrition. 2018;53:95–102. doi:.
   PubMedGoogle Scholar
• Rodriguez-Nogales A, Algieri F, Garrido-Mesa J, et al. Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition. Mol Nutr Food Res. 2017;61(11):1700144.
   Web of Science ®Google Scholar
• D’Mello C, Ronaghan N, Zaheer R, et al. Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain. J Neurosci. 2015;35(30):10821–10830. doi:.
   PubMedGoogle Scholar
• Pena JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol. 2003;5(4):277–285. doi:.
   PubMed Web of Science ®Google Scholar
• Plaza-Diaz J, Ruiz-Ojeda FJ, Vilchez-Padial LM, et al. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients. 2017;9(6):555. doi:.
   PubMed Web of Science ®Google Scholar
• Liu Y, Alookaran JJ, Rhoads JM. Probiotics in autoimmune and inflammatory disorders. Nutrients. 2018;10(10):1537. doi:.
   Google Scholar